$451.8 M

ACHN Mkt cap, 19-Sep-2018
Achillion Pharmaceuticals Net income (Q2, 2018)-37.8 M
Achillion Pharmaceuticals EBIT (Q2, 2018)-40.4 M
Achillion Pharmaceuticals Cash, 30-Jun-201835.1 M
Achillion Pharmaceuticals EV416.9 M

Achillion Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

66.1 m15 m

Revenue growth, %

(77%)

R&D expense

46.7 m53.5 m

General and administrative expense

12.7 m15.9 m

Operating expense total

59.5 m69.4 m

EBIT

(59.5 m)(69.4 m)(441.9 m)(64.9 m)

EBIT margin, %

(668%)(432%)

Interest expense

52 k37 k55 k68 k

Interest income

582 k455 k1.2 m3.2 m

Net Income

(58.9 m)(69 m)(441.9 m)(61.7 m)

Quarterly

USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

711 k711 k33.8 m

R&D expense

19.8 m13.3 m14.2 m16.7 m15.5 m18.3 m15.6 m14.8 m26.1 m

General and administrative expense

10.1 m5.4 m5.2 m4.8 m5.6 m5.4 m4.8 m5.3 m12.4 m

Operating expense total

29.9 m18.7 m19.3 m21.5 m21.1 m23.6 m20.5 m21.8 m40.4 m

EBIT

(29.2 m)(18.7 m)(19.3 m)(21.5 m)(21.1 m)(23.6 m)(20.5 m)(21.8 m)(40.4 m)

EBIT margin, %

(4105%)(2716%)(64%)

Interest expense

15 k15 k12 k27 k17 k12 k8 k12 k21 k

Interest income

225 k679 k828 k846 k1 m1.1 m1.1 m1.2 m2.6 m

Net Income

(31.7 m)(47.4 m)(19.3 m)(29 m)(22 m)(18.1 m)(18.5 m)(20.7 m)(20.2 m)(22.5 m)(19.3 m)(20.6 m)(37.8 m)

Achillion Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33.5 m73.7 m81.7 m77.3 m

Accounts Receivable

223.2 m

Inventories

2.5 m1.9 m2.7 m3.5 m

Current Assets

124.8 m154.9 m462.6 m382.5 m

Total Assets

162.4 m156.8 m464.5 m413.9 m

Accounts Payable

4.6 m6.4 m4.1 m7 m

Short-term debt

291 k195 k223 k351 k

Current Liabilities

9.4 m13.1 m14.7 m14 m

Long-term debt

56 k279 k231 k301 k

Total Debt

347 k474 k454 k652 k

Total Liabilities

14.4 m

Additional Paid-in Capital

534.5 m599.8 m905.3 m916.6 m

Retained Earnings

(381.7 m)(450.7 m)(455.7 m)(517.4 m)

Total Equity

153 m143.5 m449.6 m399.5 m

Debt to Equity Ratio

0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x

Financial Leverage

1.1 x1.1 x1 x1 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

25.6 m34.1 m33.3 m39.6 m46.7 m61.7 m150.4 m58.7 m33.8 m40.4 m43.1 m35.4 m52.1 m36.9 m35.1 m

Current Assets

141.9 m142.6 m133.6 m128.7 m255.6 m249.5 m465.3 m443 m429.1 m411.8 m383.4 m355.2 m327 m309.5 m291.9 m

PP&E

2.7 m2.6 m

Total Assets

176.1 m148 m135.2 m130.6 m279.4 m266.1 m479.5 m448.7 m432.4 m415.2 m393.4 m376.9 m360.4 m315.6 m302.8 m

Accounts Payable

4.8 m3.6 m2 m2.6 m8 m11.5 m4.9 m6.6 m5.8 m5.4 m4.1 m3 m8.1 m2.4 m1.4 m

Short-term debt

326 k256 k164 k110 k213 k216 k219 k227 k230 k234 k316 k259 k201 k151 k153 k

Current Liabilities

11.5 m9.5 m9.2 m11 m13 m23.8 m49.5 m13.5 m12.8 m13.8 m10.6 m14 m14.4 m8.1 m8.1 m

Long-term debt

110 k400 k345 k288 k173 k114 k55 k243 k207 k169 k92 k53 k

Total Debt

436 k256 k164 k110 k613 k561 k507 k400 k344 k289 k559 k466 k370 k243 k206 k

Total Liabilities

11.6 m9.5 m9.2 m11 m13.4 m24.2 m49.8 m13.8 m13.1 m14 m11 m14.3 m14.7 m8.3 m8.2 m

Additional Paid-in Capital

532.6 m536.1 m539.3 m548.6 m735.8 m740.8 m902.3 m908.2 m911.1 m913.8 m919.8 m922.7 m925.1 m931.1 m935.3 m

Retained Earnings

(368.3 m)(397.8 m)(413.4 m)(429.1 m)(469.9 m)(498.9 m)(472.7 m)(473.8 m)(492.3 m)(513 m)(537.6 m)(560.1 m)(579.5 m)(623.2 m)(640.4 m)

Total Equity

164.4 m138.4 m126 m119.6 m266 m241.9 m429.7 m434.9 m419.3 m401.2 m382.3 m362.6 m345.7 m307.3 m294.6 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1 x1 x1 x1 x1 x1 x1 x1 x

Achillion Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(58.9 m)(69 m)(5 m)(61.7 m)

Depreciation and Amortization

399 k489 k694 k955 k

Inventories

(104 k)575 k(837 k)(721 k)

Accounts Payable

315 k1.8 m(2.3 m)2.7 m

Cash From Operating Activities

(53.6 m)(55.5 m)5.6 m(65.7 m)

Purchases of PP&E

(408 k)(947 k)(704 k)(2.5 m)

Cash From Investing Activities

(65 m)43.3 m(298.7 m)60.7 m

Long-term Borrowings

(350 k)(313 k)(249 k)(246 k)

Cash From Financing Activities

133.6 m52.4 m301.1 m520 k

Interest Paid

46 k35 k50 k46 k

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(45.6 m)(16.1 m)(31.7 m)(47.4 m)(19.3 m)(48.2 m)(22 m)(18.1 m)(36.5 m)(57.3 m)(20.2 m)(42.7 m)(62 m)(20.6 m)(37.8 m)

Depreciation and Amortization

296 k111 k232 k353 k160 k321 k505 k192 k432 k690 k295 k565 k842 k289 k571 k

Accounts Payable

569 k(950 k)(2.6 m)(2 m)1.5 m5 m(1.5 m)2.4 m1.3 m1.1 m(2.7 m)(3.9 m)1.3 m(2.8 m)(3.8 m)

Cash From Operating Activities

(39.7 m)(13.4 m)(27.2 m)(39.3 m)(17.3 m)(34.2 m)21.2 m(16.2 m)(33.1 m)(48.5 m)(5.8 m)(22.7 m)(24.1 m)(37.3 m)

Cash From Investing Activities

(86.6 m)14.2 m25.7 m36.5 m(148.6 m)(6.7 m)(14.9 m)7.1 m(28.1 m)(19 m)14.4 m16.3 m27.1 m

Long-term Borrowings

(261 k)(91 k)(183 k)(237 k)(90 k)(142 k)(196 k)(54 k)(110 k)(165 k)(93 k)(186 k)(282 k)(58 k)(95 k)

Cash From Financing Activities

133.4 m(163 k)1.3 m9 m139 m141.5 m300.8 m(54 k)87 k32 k(266 k)(232 k)(291 k)1.2 m1.9 m

Interest Paid

36 k12 k20 k25 k21 k28 k39 k14 k25 k33 k17 k30 k39 k13 k21 k

Achillion Pharmaceuticals Ratios

USDY, 2018

EV/EBIT

-10.3 x

EV/CFO

-11.2 x

Financial Leverage

1 x
Report incorrect company information